Loading people...
David Bonita is a General Partner at OrbiMed, a leading global healthcare investment firm. He specializes in identifying and investing in innovative companies within the biotechnology and pharmaceutical sectors.
David Bonita primarily invests in biotechnology and pharmaceutical companies. His focus includes novel biologics, small molecule drugs, gene therapies, and other advanced medical technologies, often extending to medical devices, diagnostics, and digital health solutions.
David Bonita works as a General Partner at OrbiMed, a premier global healthcare-dedicated investment firm.
David Bonita is a General Partner at OrbiMed in New York, where he leverages his dual medical and financial background to invest in early-stage biotechnology and digital health companies. Before joining the $17 billion healthcare investment firm in 2004, he worked as a corporate finance analyst in healthcare investment banking at Morgan Stanley and UBS. He holds an AB in Biological Sciences from Harvard University and a joint MD and MBA from Columbia University. Bonita has directed investments across the life sciences sector, serving on the boards of publicly traded companies including Prelude Therapeutics, Repare Therapeutics, Third Harmonic Bio, and Enliven Therapeutics. Additionally, he held a board seat at Amunix Pharmaceuticals prior to its $1 billion acquisition by Sanofi in December 2021, highlighting his expertise in scaling biopharmaceutical platforms through major exits and public offerings.
David Bonita is a distinguished General Partner at OrbiMed, one of the world's largest and most influential healthcare-dedicated investment firms. In his pivotal role at OrbiMed, Mr. Bonita is instrumental in driving the firm's investment strategies, particularly within the dynamic and rapidly evolving life sciences landscape. His work involves a comprehensive approach to identifying, evaluating, and supporting groundbreaking companies that are poised to make significant advancements in patient care and medical innovation.
Mr. Bonita's investment focus areas are primarily concentrated on biotechnology and pharmaceuticals. He possesses a profound understanding of drug discovery, clinical development, and commercialization pathways, allowing him to discern high-potential opportunities across various therapeutic areas. This includes novel biologics, small molecule drugs, gene therapies, and other cutting-edge modalities designed to address unmet medical needs. Beyond these core areas, his expertise often extends to related sectors such as medical devices, diagnostics, and digital health solutions that complement OrbiMed's broader healthcare mandate.
His career background reflects a deep commitment to the healthcare and finance industries. Prior to his tenure at OrbiMed, David Bonita honed his analytical and strategic skills through diverse experiences that prepared him for leadership in healthcare investment. His journey typically involves a blend of scientific understanding, financial acumen, and a keen eye for market trends, which are all critical for success in the highly specialized field of life sciences investing. Professionals in his position often come from backgrounds in investment banking, venture capital, or have significant operational experience within pharmaceutical or biotech companies, providing them with a holistic perspective on the industry's challenges and opportunities.
At OrbiMed, David Bonita plays a crucial role in the firm's mission to invest across the full spectrum of healthcare companies, from seed-stage startups to large multinational corporations. He is actively involved in deal sourcing, due diligence, and portfolio management, working closely with management teams to help them achieve their strategic objectives and maximize value. While specific notable investments are often proprietary or become public knowledge over time, his work contributes to OrbiMed's track record of backing companies that bring transformative therapies and technologies to market. These investments typically aim to improve patient outcomes, enhance healthcare efficiency, and generate substantial returns for investors. His leadership helps OrbiMed maintain its position at the forefront of healthcare innovation and investment globally.
